Lyell Immunopharma, Inc.
LYEL
26 insider filings · Latest: Jun 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Jun 15 10:37 PM | Lynn SeelyDirector, President and CEO | Sale | 388 | $18.91 | $7.3K | 73,878(D) | View → |
| May 11, 2026 | Jun 15 10:35 PM | Gary K. LeeChief Scientific Officer | Sale | 130 | $18.92 | $2.5K | 17,808(D) | View → |
| May 11, 2026 | Jun 15 10:34 PM | Stephen J. HillChief Operating Officer | Sale | 89 | $18.92 | $1.7K | 17,894(D) | View → |
| May 11, 2026 | Jun 15 10:32 PM | Veronica Sanchez BulisVP, Corporate Controller | Sale | 217 | $18.91 | $4.1K | 15,420(D) | View → |
| Jun 10, 2026 | Jun 11 8:07 PM | David ShookChief Medical Officer | Sale | 1,977 | $12.64 | $25.0K | 20,923(D) | View → |
| Mar 6, 2026 | Mar 9 8:36 PM | ARCH Venture Partners IX, LLC10% Owner | Purchase | 488,090 | $25.61 | $12.5M | 1,426,528(I) | View → |
| Mar 6, 2026 | Mar 9 8:34 PM | ARCH Venture Fund XIII, L.P.10% Owner | Purchase | 488,090 | $25.61 | $12.5M | 1,426,528(I) | View → |
| Feb 11, 2026 | Feb 13 1:47 AM | Lynn SeelyDirector, President and CEO | Sale | 7,455 | $23.39 | $174.4K | 74,266(D) | View → |
| Feb 11, 2026 | Feb 13 1:46 AM | Stephen J. HillChief Operating Officer | Sale | 1,236 | $23.39 | $28.9K | 17,795(D) | View → |
| Feb 11, 2026 | Feb 13 1:44 AM | Gary K. LeeChief Scientific Officer | Sale | 1,671 | $23.39 | $39.1K | 16,938(D) | View → |
| Feb 10, 2026 | Feb 12 2:05 AM | Stephen J. HillChief Operating Officer | Sale | 109 | $23.12 | $2.5K | 19,031(D) | View → |
| Feb 10, 2026 | Feb 12 2:04 AM | Gary K. LeeChief Scientific Officer | Sale | 147 | $23.12 | $3.4K | 18,609(D) | View → |
| Feb 10, 2026 | Feb 12 2:03 AM | Lynn SeelyDirector, President and CEO | Sale | 438 | $23.12 | $10.1K | 81,721(D) | View → |
| Feb 10, 2026 | Feb 12 2:00 AM | Veronica Sanchez BulisVP, Corporate Controller | Sale | 254 | $23.12 | $5.9K | 15,637(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | Jun 12 8:25 PM | William JL RieflinDirector | Grant/Award | 9,250 | $13.22 | 9,250(D) | View → |
| Jun 10, 2026 | Jun 12 8:23 PM | Sumant RamachandraDirector | Grant/Award | 9,250 | $13.22 | 9,250(D) | View → |
| Jun 10, 2026 | Jun 12 8:22 PM | Elizabeth G NabelDirector | Grant/Award | 9,250 | $13.22 | 9,250(D) | View → |
| Jun 10, 2026 | Jun 12 8:21 PM | Richard KlausnerDirector | Grant/Award | 9,250 | $13.22 | 9,250(D) | View → |
| Jun 10, 2026 | Jun 12 8:19 PM | Cathy FriedmanDirector | Grant/Award | 9,250 | $13.22 | 9,250(D) | View → |
| Jun 10, 2026 | Jun 12 8:17 PM | Otis W BrawleyDirector | Grant/Award | 9,250 | $13.22 | 9,250(D) | View → |
| Jun 10, 2026 | Jun 12 8:16 PM | Mark BachledaDirector | Grant/Award | 9,250 | $13.22 | 9,250(D) | View → |
| Mar 9, 2026 | Mar 16 11:26 PM | Smital ShahChief Fin. and Bus. Officer | Grant/Award | 140,000 | $25.50 | 140,000(D) | View → |
| Feb 10, 2026 | Feb 12 2:05 AM | Stephen J. HillChief Operating Officer | Grant/Award | 65,000 | $23.71 | 65,000(D) | View → |
| Feb 10, 2026 | Feb 12 2:04 AM | Gary K. LeeChief Scientific Officer | Grant/Award | 50,000 | $23.71 | 50,000(D) | View → |
| Feb 10, 2026 | Feb 12 2:03 AM | Lynn SeelyDirector, President and CEO | Grant/Award | 155,000 | $23.71 | 155,000(D) | View → |
| Feb 10, 2026 | Feb 12 2:01 AM | Mark A MeltzGeneral Counsel | Grant/Award | 50,000 | $23.71 | 50,000(D) | View → |
| Feb 10, 2026 | Feb 12 1:58 AM | David ShookChief Medical Officer | Grant/Award | 50,000 | $23.71 | 50,000(D) | View → |